Terbinex with Eco Formula (hydroxypropyl chitosan / terbinafine topical) Disease Interactions
There are 6 disease interactions with Terbinex with Eco Formula (hydroxypropyl chitosan / terbinafine topical):
Terbinafine (Includes Terbinex with Eco Formula) ↔ Liver Disease
Severe Potential Hazard, High plausibility
Applies to: Liver Disease
Oral terbinafine is not recommended for use in patients with chronic or active liver disease. Terbinafine may be hepatotoxic. Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease. Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.
References
- Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993): 248
- "Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
- Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992): 259-84
Terbinafine (Includes Terbinex with Eco Formula) ↔ Neutropenia
Severe Potential Hazard, Low plausibility
Applies to: Neutropenia
Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine. A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care. Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia. It may be appropriate to monitor blood counts more frequently during terbinafine therapy. If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.
References
- Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994): 806
- "Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Terbinafine (Includes Terbinex with Eco Formula) ↔ Depression
Moderate Potential Hazard, Moderate plausibility
Applies to: Depression
Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets. Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms. Patients and caregivers should be instructed to report any depressive symptoms.
Terbinafine (Includes Terbinex with Eco Formula) ↔ Immunosuppression
Moderate Potential Hazard, Moderate plausibility
Applies to: Immunodeficiency
Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials. The clinical significance of these decreases is unknown. Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.
References
- "Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
- Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994): 806
Terbinafine (Includes Terbinex with Eco Formula) ↔ Lupus
Moderate Potential Hazard, Moderate plausibility
Applies to: Lupus Erythematosus
Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets. Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.
Terbinafine (Includes Terbinex with Eco Formula) ↔ Renal Dysfunction
Moderate Potential Hazard, Moderate plausibility
Applies to: Renal Dysfunction
The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended. Terbinafine metabolites are primarily eliminated by the kidney. The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.
References
- Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989): 110-3
- "Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Terbinex with Eco Formula (hydroxypropyl chitosan / terbinafine topical) drug Interactions
There are 307 drug interactions with Terbinex with Eco Formula (hydroxypropyl chitosan / terbinafine topical)
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
